Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2011 1
2012 1
2015 1
2016 2
2017 1
2018 4
2019 6
2020 5
2021 3
2022 6
2023 8
2024 5
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Conflict of Interest Disclosures.
[No authors listed] [No authors listed] Global Spine J. 2023 May;13(2_suppl):568S-591S. doi: 10.1177/21925682231173597. Global Spine J. 2023. PMID: 37222100 Free PMC article. No abstract available.
Molecular basis of rare congenital bleeding disorders.
Dorgalaleh A, Bahraini M, Shams M, Parhizkari F, Dabbagh A, Naderi T, Fallah A, Fazeli A, Ahmadi SE, Samii A, Daneshi M, Heydari F, Tabibian S, Tavasoli B, Noroozi-Aghideh A, Tabatabaei T, Gholami MS. Dorgalaleh A, et al. Blood Rev. 2023 May;59:101029. doi: 10.1016/j.blre.2022.101029. Epub 2022 Nov 9. Blood Rev. 2023. PMID: 36369145 Review.
Rare bleeding disorders (RBDs), including factor (F) I, FII, FV, FVII, combined FV and FVIII (CF5F8), FXI, FXIII and vitamin-K dependent coagulation factors (VKCF) deficiencies, are a heterogeneous group of hemorrhagic disorder with a variable bleeding tendency. ...
Rare bleeding disorders (RBDs), including factor (F) I, FII, FV, FVII, combined FV and FVIII (CF5F8), FXI, FXIII and vitamin-K depend …
Characterization of Ebola Virus-Associated Eye Disease.
Eghrari AO, Bishop RJ, Ross RD, Davis B, Larbelee J, Amegashie F, Dolo RF, Prakalapakorn SG, Gaisie C, Gargu C, Sosu Y, Sackor J, Cooper PZ, Wallace A, Nyain R, Gray M, Kamara F, Burkholder B, Brady CJ, Ray V, Tawse KL, Yeung I, Neaton JD, Higgs ES, Lane HC, Reilly C, Sneller MC, Fallah MP. Eghrari AO, et al. JAMA Netw Open. 2021 Jan 4;4(1):e2032216. doi: 10.1001/jamanetworkopen.2020.32216. JAMA Netw Open. 2021. PMID: 33399856 Free PMC article.
DESIGN, SETTING, AND PARTICIPANTS: This baseline cross-sectional analysis of survivors of EVD and their close contacts was conducted within PREVAIL III, a 5-year, longitudinal cohort study. Participants who enrolled at John F. Kennedy Medical Center in Liberia, West Africa …
DESIGN, SETTING, AND PARTICIPANTS: This baseline cross-sectional analysis of survivors of EVD and their close contacts was conducted within …
What defines response to vagus nerve stimulation in children with drug-resistant epilepsy? A prospective cohort study from the CONNECTiVOS collaboration.
Niazi F, Mithani K, Suresh H, Wong SM, Yau I, McRae L, Dinger TF, Rutka JT, Ochi A, Otsubo H, Weiss S, Sham L, Donner E, Chau V, Hadjinicolaou A, Major P, Weil AG, Tailor J, Abel TJ, Remick M, Akwayena E, Schrader D, Bollo RJ, Smyth MD, Aum D, Lew S, Wang S, Niazi T, Raskin JS, Widjaja E, Weiner HL, Gadgil N, LoPresti MA, Albert GW, Fallah A, Kerr E, Smith ML, Jain P, Ibrahim GM. Niazi F, et al. Epilepsia. 2025 Oct;66(10):3700-3715. doi: 10.1111/epi.18520. Epub 2025 Jun 26. Epilepsia. 2025. PMID: 40574479 Free PMC article.
Minimal and robust clinically important difference of three fatigue measures in chronic stroke survivors.
Cheraghifard M, Sarlak N, Taghizadeh G, Azad A, Fallah S, Akbarfahimi M. Cheraghifard M, et al. Top Stroke Rehabil. 2023 Jul;30(5):522-531. doi: 10.1080/10749357.2022.2051830. Epub 2022 Mar 29. Top Stroke Rehabil. 2023. PMID: 35350961
OBJECTIVE: To identify the minimal clinically important difference (MCID) and robust clinically important difference (RCID) of FAS, POMS-F, and SF-36-VT in stroke survivors. METHODS: Participants completed the FAS, POMS-F, and SF-36-VT before and after receiving 6-w …
OBJECTIVE: To identify the minimal clinically important difference (MCID) and robust clinically important difference (RCID) of FAS, POMS- …
Transcranial Magnetic Stimulation Facilitates Neural Speech Decoding.
Comstock L, Carvalho VR, Lainscsek C, Fallah A, Sejnowski TJ. Comstock L, et al. Brain Sci. 2024 Sep 2;14(9):895. doi: 10.3390/brainsci14090895. Brain Sci. 2024. PMID: 39335391 Free PMC article.

Overall, task accuracy was a significant predictor of decoding accuracy for phoneme categories (F(1,135) = 11.51, p < 0.0009) and individual phonemes (F(1,119) = 13.56, p < 0.0003), providing new evidence for a causal link between TMS, neural function, and beh

…

Overall, task accuracy was a significant predictor of decoding accuracy for phoneme categories (F(1,135) = 11.51, p < 0.0009) and

…
Therapeutic potential of phospho-thiadiazole derivatives as anti-glioblastoma agents: synthesis, biological assessment and computational study.
Gholivand K, Faraghi M, Fallah N, Babaei A, Pirastehfar F, Dusek M, Eigner V, Salimi F. Gholivand K, et al. Bioorg Chem. 2022 Dec;129:106123. doi: 10.1016/j.bioorg.2022.106123. Epub 2022 Sep 5. Bioorg Chem. 2022. PMID: 36108588
In this study, three new phospho thiadiazole compounds (A, F and W) were investigated as possible cytotoxic agents. The compounds were synthesised and characterised by using spectroscopy methods. ...
In this study, three new phospho thiadiazole compounds (A, F and W) were investigated as possible cytotoxic agents. The compounds wer …
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer.
Chang E, Hahn NM, Lerner SP, Fallah J, Agrawal S, Kamat AM, Bhatnagar V, Svatek RS, Jaigirdar AA, Bross P, Shore N, Kates M, Sachse K, Brewer JR, O'Donnell MA, Steinberg GD, Viviano CJ, Bloomquist E, Ribal MJ, Galsky MD, Oliver R, Black PC, Al-Ahmadie H, Brothers K, Pohar K, Dinney CP, Feng Z, Downs TM, Porten SP, Smith AB, Bangs R, Psutka SP, Agarwal N, Amiri-Kordestani L, Suzman DL, Pazdur R, Kluetz PG, Weinstock C. Chang E, et al. Bladder Cancer. 2023 Sep 25;9(3):271-286. doi: 10.3233/BLC-230056. eCollection 2023. Bladder Cancer. 2023. PMID: 38993184 Free PMC article.
Estro G-100 herbal extract and hot flashes in postmenopausal women: A randomized double-blinded controlled trial.
Farzaneh F, Fallah G, Khalili-Chelik A, Fallah A, Hosseini M. Farzaneh F, et al. Explore (NY). 2024 May-Jun;20(3):334-339. doi: 10.1016/j.explore.2023.09.004. Epub 2023 Sep 19. Explore (NY). 2024. PMID: 37778911 Clinical Trial.
Finally, the frequency and severity of hot flashes (F&S) were subjectively reported and compared weekly during the treatment for 12 weeks. ...
Finally, the frequency and severity of hot flashes (F&S) were subjectively reported and compared weekly during the treatment for …
40 results